Duration of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in mean duration of episodes compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Kilic 2009 (interferon-alpha lozenges 1000 IU or 2000 IU vs placebo, 84 patients; high risk of selective reporting): the data presented did not allow analysis; authors reported no statistically significant difference…
1 study · 84 participants
GRADE not reported
Quality of life · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Positive response (not defined) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Triamcinolone acetonide 0.1% ointment (topical) led to higher positive response (not defined) compared with phenytoin syrup mouthwash (30 mg in 5 mL); GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Time to complete healing · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in healing time compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Number of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in number of episodes compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Pain (0-3 scale) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in pain (0-3 scale) compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Global aphthae count and pain score · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Matsuda 2003 (rebamipide 300 mg daily vs placebo, 35 patients; high risk of reporting bias; concomitant treatments): authors stated that rebamipide improved the global evaluation aphthae count and global evaluation…
1 study · 35 participants
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomesInterferon-alpha dose comparison
Kilic 2009 (interferon-alpha 1000 IU vs 2000 IU lozenges, 84 patients): the data presented did not allow analysis; authors reported no statistically significant difference in total ulcer burden between the two doses.
1 study · 84 participants
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Hamuryudan 1998: significant adverse effects including severe sedation, polyneuropathy, loss of libido, and weight gain; a greater number of adverse events was seen for the higher (300 mg) dose; 4 patients withdrew due…
1 study · 101 participants
GRADE not reported
Number of painful days · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in number of painful days compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Functional outcomes · Children and adolescents with femoral shaft fractures
1 finding from 1 review
Unacceptable malunion · Children and adolescents with femoral shaft fractures
Surgical interventions probably leads to lower unacceptable malunion Assessed by imaging compared with conservative interventions (moderate certainty).
1 finding from 1 review
Serious adverse events · Children and adolescents with femoral shaft fractures
Surgical interventions may leads to higher serious adverse events compared with conservative interventions (low certainty).
1 finding from 1 review
Time to return to usual activities⁶(time to return to school) · Children and adolescents with femoral shaft fractures
1 finding from 1 review
Child satisfaction Assessed by an ordinal rating scale (11 points): very unhappy to very happy · Children and adolescents with femoral shaft fractures
1 finding from 1 review
Parent satisfaction Rated as excellent or good · Children and adolescents with femoral shaft fractures
Surgical interventions may leads to higher parent satisfaction Rated as excellent or good compared with conservative interventions (low certainty).
1 finding from 1 review